Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab and Pembrolizumab in Relapsed, Refractory Diffuse Large-B Cell Lymphoma
NCT03309878Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2018
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of mogamulizumab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose or Recommended Phase II Dose at 6 weeks, Incidence of Adverse Events at 25 months and 1 more. Started Oct 2018; status: completed.
02
Drugs
mogamulizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03309878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03309878.